cysteine hydrochloride · Baxter Hlthcare Corp · NDA 212535
Nouress
Earliest generic entry, as listed
15 Mar 2039
Blocked by patent: US 10493051, US 10543186, US 10702490, US 11045438.
Listed patents · 20 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10493051 | drug product · sets the listed date | 15 Mar 2039 |
| US 10543186 | use U-2722 · sets the listed date | 15 Mar 2039 |
| US 10702490 | drug product · sets the listed date | 15 Mar 2039 |
| US 11045438 | drug product · sets the listed date | 15 Mar 2039 |
| US 11510941 | drug product | 2 Mar 2039 |
| US 10478453 | drug product, use U-2752 | 15 Jan 2039 |
| US 10583155 | drug product, use U-2752 | 15 Jan 2039 |
| US 10653719 | drug product | 15 Jan 2039 |
| US 10905713 | drug product | 15 Jan 2039 |
| US 10905714 | drug product | 15 Jan 2039 |
| US 10912795 | drug product | 15 Jan 2039 |
| US 10918662 | drug product | 15 Jan 2039 |
| US 10933089 | drug product | 15 Jan 2039 |
| US 11510942 | drug product, use U-2752 | 15 Jan 2039 |
| US 11642370 | drug product | 15 Jan 2039 |
| US 11648262 | drug product | 15 Jan 2039 |
| US 11679125 | drug product | 15 Jan 2039 |
| US 11684636 | drug product | 15 Jan 2039 |
| US 11826383 | drug product | 15 Jan 2039 |
| US 12569514 | drug product | 15 Jan 2039 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212535 · 001 · RLD | solution, intravenous | 500MG/10ML (50MG/ML) | 15 Mar 2039 |